托法西提尼布与勒夫卢诺米德联合治疗耐火性塔卡亚苏动脉炎的治疗效果:试点研究
Shuwai Chang1, Xiufang Kong1, Lingying Ma1
1Department of Rheumatology and Immunology, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Seminars in arthritis and rheumatism
|March 14, 2026
概括
托法西提尼布 (TOF) 与莱夫卢诺米德 (LEF) 结合使用,在耐火性塔卡亚苏动脉炎 (TAK) 方面表现有前途. 这种组合疗法实现了高缓解率,并允许在患有这种具有挑战性的自身免疫性疾病的患者中逐渐减少葡萄糖皮质激素 (GC).
科学领域:
- 风湿病学和免疫学
- 血管炎症 血管炎症
- 自免疫性疾病 自免疫性疾病
背景情况:
- 塔卡亚苏动脉炎 (TAK) 是一种慢性炎症状况,影响大动脉,经常导致耐火性疾病,复发和依赖葡萄糖皮质激素.
- 现有的耐火TAK治疗方法存在局限性,需要探索新的治疗策略.
- 托法西替尼 (TOF) 和莱夫卢诺米德 (LEF) 的组合为管理这种复杂的血管炎提供了潜在的新方法.
研究的目的:
- 评估托法西替尼 (TOF) 和莱夫卢诺米德 (LEF) 联合治疗方案的疗效和安全性,用于耐火性塔卡亚苏动脉炎 (TAK) 患者.
- 评估这种新型治疗方案在改善TAK患者临床结果和减少葡萄糖皮质激素 (GC) 依赖方面的潜力.
- 提供支持TOF+LEF作为耐火TAK的可行治疗策略的数据.
主要方法:
- 来自东中国高山关节炎 (ECTA) 队列的24名耐火TAK患者的回顾性分析 (2020年5月 - 2024年8月).
- 患者接受了托法西替尼 (TOF) 和莱夫卢诺米德 (LEF) 的组合,大多数患者也接受了葡萄糖皮质类药物 (GC).
- 在12个月内评估的结果包括缓解率,GC逐渐缩小,炎症标志物减少 (ESR),血管成像变化 (MRA) 和不良事件.
主要成果:
- 观察到高缓解率:87.5%在6个月和79.2%在12个月.
- 葡萄糖皮质体 (GC) 剂量显著降低 (从15.2±12.9毫克/天降至6.5±4.5毫克/天在12个月后,p=0.001) 和红细胞沉率 (ESR) (p=0.02).
- 治疗方案耐受性良好,在71.4%的评估患者中,血管成像 (MRA) 稳定或改善,复发率低 (8.3%).
结论:
- 托法西替尼 (TOF) 和莱夫卢诺米德 (LEF) 的组合在实现缓解和降低耐火塔卡亚苏动脉炎 (TAK) 中的GC依赖性方面表现出显著的疗效.
- 这种疗法似乎是一个有前途的,耐受性良好的新疗法选择,用于治疗耐火性TAK患者.
- 需要进一步的前性研究来证实这些发现,并确定TOF + LEF在TAK管理中的长期益处.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
697
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
697
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
639
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
639
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
596
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
596
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
532
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
532
Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
615
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615


